Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Pharmaceutical Contract Win

14 Jan 2009 07:00

RNS Number : 5695L
Imaginatik PLC
14 January 2009
 



14 January 2009

Imaginatik Plc

("Imaginatik" or the "Company")

Pharmaceutical Contract Win

Imaginatik plc (AIM: IMTK), a leading provider of cost reduction, process improvement and collaborative innovation software and processes, is pleased to announce it has secured an annual contract with one of the world's leading pharmaceutical companies.

The annual contract, for 5,000 seats, is further evidence of the Company's strong presence within the pharmaceutical industry with the new client joining the likes of Pfizer, Merck, Novartis and Solvay on Imaginatik's client list. Imaginatik now provides its collaborative software to six of the world's top pharmaceutical companies, assisting those companies in harnessing the knowledge of their thousands of employees to identify potential new products, areas of cost-reduction and process enhancements. 

Under the terms of the contract, Imaginatik will be implementing its core product, Idea Central, across a number of divisions within the client, including Research, Prescription Medicine and IT. Idea Central will play a key role in delivering process and product improvement within these divisions.

A spokesperson for the client commented, "In furthering our emphasis on Value through Innovation, Imaginatik's Idea Central provided a focal point for idea generation and sharing, streamlined our reviewing process, and served as a vehicle for ongoing communication. We found Imaginatik's software and services to be particularly effective."

Mark Turrell, CEO of Imaginatik plc commented, "We are delighted to see the investment placed on strengthening our sales team being rewarded with significant annual contract wins which add to our increasingly impressive recurring revenue figure. This contract also once again demonstrates the value of our collaborative software to the pharmaceutical industry and we are confident that this will continue to be an excellent vertical for Imaginatik going forward."

For further information please contact:

Imaginatik plc

Tel: 020 7917 2975

Mark Turrell, CEO / Shawn Taylor, CFO

WH Ireland Limited

Tel: 0121 265 6330

Tim Cofman / Katy Birkin

ICIS

Tel: 020 7651 8688

Caroline Evans-Jones / Mike Smith

About Imaginatik

Imaginatik is the leading provider of cost reduction, process improvement and collaborative innovation software and processes to the world's leading companies. More than 100 clients rely on Imaginatik's software, consulting and research to enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's software and consulting services have helped clients discover significant sources of additional revenue, as well as tangible cost savings, process improvements and increased product pipeline. Imaginatik is also committed to developing strategic solutions in the field of innovation, working with academic institutions such as the London Business School and the Cass School of Business, London, as well as leading practitioners of corporate innovation.

For further information please visit www.imaginatik.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUOOVRKORAAAR
Date   Source Headline
19th Dec 20083:16 pmRNSDirector/PDMR Shareholding
18th Dec 20089:45 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSShare Option Schemes
1st Dec 20087:00 amRNSDirector's Disclosure Update
19th Nov 200812:39 pmRNSDirectors Dealing
13th Nov 20087:00 amRNSInterim Results
14th Oct 20087:00 amRNSTrading Statement
2nd Oct 20087:00 amRNSContract Win
30th Sep 20084:30 pmRNSTotal Voting Rights
24th Sep 20087:00 amRNSDirector/PDMR Shareholding
15th Sep 20087:00 amRNSContract Win
3rd Sep 20087:00 amRNSIssue of Equity
21st Aug 20087:00 amRNSContract Win
28th Jul 20089:27 amRNSNon-Executive Retirement
10th Jul 200810:20 amRNSResult of AGM
10th Jul 20087:00 amRNSAGM Statement
24th Jun 20087:00 amRNSDirector/PDMR Shareholding
18th Jun 200810:05 amRNSAnnual Report and Accounts
13th Jun 200812:16 pmRNSDirector/PDMR Shareholding
11th Jun 20087:00 amRNSFinal Results
1st Apr 200811:52 amRNSDirector Dealings
31st Mar 20084:30 pmRNSTotal Voting Rights
17th Mar 20082:57 pmRNSShare Subscription - Update
10th Mar 20082:23 pmRNSShare Subscription
10th Mar 20089:30 amRNSHolding(s) in Company
28th Feb 200810:01 amRNSPfizer Update
13th Feb 20089:40 amRNSTrading Statement
22nd Jan 20089:30 amRNSWorld Economic Forum
11th Jan 200810:13 amRNSMajor Contract Wins
30th Nov 20072:41 pmRNSWEF Technology Pioneer
14th Nov 20072:12 pmRNSInterim Results
16th Aug 200711:05 amRNSAgreement With IBM
14th Aug 20074:55 pmRNSAIM Rule 26 Information
27th Jul 200710:46 amRNSAGM Statement
27th Jul 20077:01 amRNSAGM Statement
11th Jul 200712:00 pmBUSGlobal Competition Forces Innovation and Collaboration Acceleration
29th Jun 20073:33 pmRNSAnnual Report and Accounts
13th Jun 200711:50 amRNSResult of EGM
12th Jun 20077:02 amRNSFinal Results
4th Jun 20077:02 amRNSUK & European Contract Wins
1st Jun 200710:29 amRNSNotice of Results
18th May 200710:05 amRNSNotice of EGM
23rd Apr 20072:38 pmBUSImaginatik Wins a Queens Award for Enterprise
23rd Apr 200711:02 amRNSWins A Queens Award
19th Apr 200710:59 amRNSDirector/PDMR Shareholding
21st Mar 20077:04 amRNSSenior Management Appointment
21st Mar 20077:01 amBUSImaginatik Appoints President, Americas and New CMO to Accommodate Growth
16th Mar 200711:45 amRNSTrading Statement
9th Feb 200711:30 amBUSImaginatik Appoints Managing Director in United Kingdom
9th Feb 20077:00 amRNSAppointment of UK MD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.